"I, among others in the industry, are very concerned that Trump's news of rescheduling is a false flag," said Josh Kesselman, publisher of High Times and founder of RAW Rolling Papers. Kesselman warned that moving THC to Schedule III could allow pharmaceutical companies to dominate the market with synthetic THC while subjecting dispensaries and growers to enforcement under the Food, Drug, and Cosmetic Act. "Rescheduling will further stack the odds against small operators," said Harrison Bard, CEO and Co-Founder of Custom Cones USA and DaySavers, though he emphasized the importance of expanded recognition for veterans who rely on medical cannabis.
Author: Zachary Bynum
Published at: 2025-12-14 19:44:57
Still want to read the full version? Full article
